Daily dose to organs at risk predicts acute toxicity in pancreatic stereotactic radiotherapy

Acta Oncol. 2020 Aug;59(8):944-948. doi: 10.1080/0284186X.2020.1742931. Epub 2020 Mar 24.

Authors

Mauro Loi¹, Alba Magallon-Baro¹, Mustafa Suker², Casper Van Eijck², Mischa Hoogeman¹, Joost J Nuyttens¹

Affiliations

¹ Department of Radiotherapy, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.
² Department of Surgery, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.

PMID: 32207351
DOI: 10.1080/0284186X.2020.1742931

No abstract available

Publication types

Clinical Trial, Phase II
Letter

MeSH terms

Abdominal Pain
Acute Disease
Adenocarcinoma / pathology
Adenocarcinoma / radiotherapy*
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Data Analysis
Diarrhea / etiology
Fluorouracil / adverse effects
Humans
Irinotecan / adverse effects
Leucovorin / adverse effects
Middle Aged
Nausea / etiology
Organs at Risk / radiation effects*
Oxaliplatin / adverse effects
Pancreatic Neoplasms / pathology
Pancreatic Neoplasms / radiotherapy*
Prospective Studies
Radiation Dosage
Radiosurgery / adverse effects*
Time Factors

Substances

folfirinox
Oxaliplatin
Irinotecan
Leucovorin
Fluorouracil